17 results about "Lipid level" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

The invention belongs to the technical field of biological medicines, and particularly relates to a daphniphyllum calycinum extract compound, an extraction method thereof and application of the daphniphyllum calycinum extract compound in preparation of a medicine for preventing or treating non-alcoholic fatty liver diseases. A natural compound with a novel structure is obtained from daphniphyllum calycinum for the first time, a preparation method of the compound is provided, activity research is carried out on the compound, and experimental data shows that the compound is low in cytotoxicity and has no obvious cytotoxicity to normal cells, and the compound can be used for preparing the compound by inhibiting expression of fatty acid synthetases ACC, ACLY and FAS. The compound inhibits the de novo synthesis of fatty acid in cells, thereby inhibiting the accumulation of lipid droplets in the cells and reducing the lipid level in the cells, and has wide application prospects in the field of preparation of drugs for preventing or treating non-alcoholic fatty liver diseases.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels. 20 24 20 26 17 22 A pr 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 6 1 7 2 2 A p r 2 0 2 4

Pharmaceutical compositions comprising a C1-C4 alkyl ester azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), di-isopropyl azelate (DiPA), di-isobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and methods of, inter alia, improving abnormal lipid levels and treating or preventing dyslipidemias and / or diseases of conditions associated therewith comprising administering to a subject such pharmaceutical compositions, are provided.

Disclosed herein are compositions, constructs, cassettes, vectors, cells, nucleic acids, peptides, proteins, protocols and methods for reducing cholesterol and lipid buildup in mammalian subjects, via gene and / or cell therapeutic treatments. In many embodiments, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods may help to reduce lipid levels in mammals. In one embodiment, the disclosed compositions, cells, constructs, cassettes, vectors, nucleic acids, peptides, proteins, protocols and methods are useful in reducing lipid build-up, especially cholesterol, in liver cells.

This invention provides nanoparticles with plaque-targeting function, their preparation method, and their application in the preparation of anti-atherosclerotic drugs, belonging to the field of composite nanomaterials technology. The plaque-targeting nanoparticles provided by this invention comprise a core and a shell. The core is ZIF-8 nanoparticles loaded with neoindocyanine green, and the shell is arginine-modified polydopamine; the surface of the shell is modified with hyaluronic acid. The plaque-targeting nanoparticles provided by this invention can regulate lipid levels by simultaneously intervening in multiple pathways, providing anti-inflammatory effects, protecting damaged endothelial cells, and enabling low-temperature (42-45℃) photothermal therapy combined with anti-nlrp3 therapy. This treats atherosclerosis by regulating PCSK9 pathway-induced lipid accumulation and repairing damaged endothelial cells.

This invention relates to a compound extracted from *Dryopteris macrocarpa*, its extraction method, and its application in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease. This invention provides a novel natural compound obtained from *Dryopteris macrocarpa* for the first time, along with a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity to normal cells. It can inhibit fatty acid uptake in cells by suppressing the expression of fatty acid uptake-related genes FATP2 and CD36, thereby inhibiting lipid droplet accumulation and reducing cellular lipid levels. This compound can be applied in the preparation of drugs for the prevention and / or treatment of non-alcoholic fatty liver disease.

This invention, through lipidomics and clinical sample validation, found that prospective follow-up of pre-pregnancy serum samples from women with a history of recurrent pregnancy loss (RPL) revealed that the pre-pregnancy serum levels of phosphatidylinositol PI (18:1 / 18:1) (i.e., PI 36:2), phosphatidylcholine (29:0-6:0) (i.e., PC 35:0), phosphatidylethanolamine (18:1p-18:2) (i.e., PE 36:3p), triglycerides (28:1-10:4-11:2) (i.e., TG 49:7), triglycerides (14:0-18:2-20:5) (i.e., TG 52:7), and wax esters (22:1) (i.e., WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. This confirms that the pre-pregnancy serum levels of these six lipids (PI 36:2, PC 35:0, PE 36:3p, TG 49:7, TG 52:7, WE 22:1) were significantly lower in these women than in those who subsequently achieved successful pregnancies. Decreased levels of 22:1 lipids were significantly associated with the risk of miscarriage in subsequent pregnancies. The area under the curve (AUC) of the predictive model constructed by combining six lipids reached 0.85, demonstrating good predictive efficacy. Based on these findings, this lipid combination can serve as a reliable predictor of miscarriage risk in subsequent pregnancies in RPL patients and can be used to develop diagnostic reagents or kits for preconception risk screening.

The present invention provides a pharmaceutical composition comprising a C1-C4 alkyl azelate, such as diethyl azelate (DEA), dimethyl azelate (DMA), diisopropyl azelate (DiPA), diisobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), such as dioctyl azelate (DEA), dimethyl azelate (DMA), diisopropyl azelate (DiPA), diisobutyl azelate (DiBuA), and di-2-pentyl azelate (D2PA), and, in particular, methods of ameliorating abnormal lipid levels and treating or preventing dyslipidemia or a disease or condition associated with dyslipidemia comprising administering such pharmaceutical compositions to a subject.

This invention relates to the field of biomedical technology, disclosing extracellular vesicles derived from Poria cocos and their application in the development and preparation of drugs for the prevention or treatment of metabolic-associated steatohepatitis (MAS). The drugs improve liver tissue morphology and pathological lesions, regulate serum and liver lipid levels and inflammatory factor levels, and regulate mitochondrial structure and function, including alleviating mitochondrial ultrastructural damage, increasing the number of autophagosomes, improving oxidative stress and energy metabolism, promoting the expression of mitochondrial autophagy-related proteins, and reducing the production and efflux of Ox-mtDNA, thereby inhibiting the expression of NLRP3 inflammasome-related proteins. These drugs can improve MAS and provide a new direction for the development and research of drugs for the prevention and treatment of MAS.

The present invention relates to the polyherbal composition for optimum vascular activity and cardiac health. The Invention also provides its method of preparation. The composition exhibits beneficial effects in regulating dyslipidaemia, controlling and reducing arterial fat deposition along with reducing elevated levels of serum cholesterol, triglycerides and associated atherosclerosis. The composition also regulates lipid levels and promotes cardiovascular health, as well as improves overall cardiac function.

The invention belongs to the technical field of microorganisms, preparations and efficient culture, and particularly relates to a bacterial strain for lowering lipid and improving metabolism-related fatty liver diseases, a preparation, application and an efficient culture method, the bacterial strain cultured and preserved and a corresponding product can be used for lowering lipid and improving metabolism-related fatty liver diseases, and by promoting secretion of pantothenic acid, the lipid-lowering and metabolism-related fatty liver diseases can be improved. According to the present invention, the liver lipid level is reduced, the liver injury is relieved, the metabolism-related fatty liver disease is treated, the metabolic disorder caused by the high fat diet is improved, the levels of inflammatory factors TNF-alpha and IL-6 are reduced, the LPS production is reduced, the liver inflammatory reaction is reduced, and the lipid level in the body is reduced by reducing the TC, TG and L-DLC in the plasma and the liver and recovering the AST and ALT levels in the liver, such that the in-vivo lipid level is reduced, the liver injury is relieved, the metabolism-related fatty liver disease is treated, and the metabolic disorder caused by the high fat diet is improved; in addition, a certain amount of inonotus obliquus polysaccharide is added into the culture medium, so that the yield of the strain is remarkably increased, and the growth speed of the logarithmic phase is promoted.

Applicant discloses herein methods and reagents for treating isolated livers, or isolated liver portions, prior to transplantation into a subject in need of a liver transplant, to prepare and maintain these isolated livers and portions for liver transplantation, and to reduce liver fat in these livers. The methods comprise perfusing an isolated liver or liver portion with a solution containing a pyrimidine cyclohexyl compound (e.g., miricorilant) or a pyrimidine cyclohexenyl compound (e.g., CORT125385). The reagents for the uses and methods disclosed herein contain a pyrimidine cyclohexyl compound or a pyrimidine cyclohexenyl compound. Perfusion with miricorilant-containing reagents improved lactate clearance. Perfusion of isolated livers with these reagents increased lipid levels in the perfusate as compared to their initial levels. Improved lactate clearance and increased lipid levels in the perfusate are believed to indicate reduced fat levels in the isolated liver, and to indicate improved suitability of these livers for transplantation.

The present invention relates to a composition for preventing or treating lipid metabolism-related diseases comprising ginger juice and lemon juice as active ingredients. The activities of a mixed solution of ginger juice and lemon juice in improving the lipid levels in plasma, the lipid levels in the liver, and the lipid levels in feces, and in inhibiting lipid deposition in the aorta were analyzed, and the activity of the active ingredients in ginger juice and lemon juice as inhibitors against target receptors, and the physicochemical and pharmacokinetic properties thereof were analyzed, whereby it was confirmed that ginger juice and lemon juice can be used for preventing, alleviating, or treating lipid metabolism-related diseases.

The invention relates to a dryopteris gigantean extraction compound, an extraction method thereof and application of the dryopteris gigantean extraction compound in preparation of drugs for preventing and / or treating non-alcoholic fatty liver diseases. A natural compound with a novel structure is obtained from dryopteris crassipes for the first time, a preparation method of the compound is provided, activity research is carried out on the compound, and experimental data shows that the compound has low toxicity to normal cells, and can inhibit the uptake of fatty acid in cells by inhibiting the expression of fatty acid uptake related genes FATP2 and CD36, so that the activity of the fatty acid in the cells is inhibited, and the activity of the fatty acid in the cells is inhibited. Therefore, lipid droplet accumulation in cells is inhibited, lipid level in cells is reduced, and the compound can be applied to the field of preparation of drugs for preventing and / or treating non-alcoholic fatty liver diseases.

The application discloses application of a Solanum torvum extract in preparation of a medicine for preventing and treating non-alcoholic fatty liver and indications thereof, and the Solanum torvum extract comprises one or both of a Solanum torvum water extract and a Solanum torvum alcohol extract; the application is proved by experiments that the Solanum torvum alcohol extract can obviously reduce the weight of a non-alcoholic fatty liver NAFLD mouse; the Solanum torvum water extract can obviously reduce the inguinal white fat; the Solanum torvum extract can obviously reduce a liver weight / body weight index, a liver triglyceride (TG) content, liver lipid deposition, and liver function damage indexes, i.e., glutamic-oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT). The Solanum torvum extract can also reduce serum triglyceride (TG) and cholesterol (TC) levels of the mouse, improve lipid levels, and therefore has an important role in treating non-alcoholic fatty liver.